Peng Cheng

Dr. Peng Cheng


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
PCPeng Cheng
Peng Cheng
YCYing Chen
Ying Chen
THTian-Lin He
Tian-Lin He
CWChao Wang
Chao Wang
SGShi-Wei Guo
Shi-Wei Guo
YZYi-Jie Zhang
Yi-Jie Zhang
Menin displays either tumor suppression or promotion functions in a context-dependent manner. Previously, we proposed that Menin acts as a tumor suppressor by inhibiting cell growth in pancreatic ductal adenocarcinoma (PDAC), whereas the relationship between the Menin expression and overall survival rate of PDAC patients has not been completely elucidated, indicating the complexity of Menin functions in PDAC progression. Here, we identify Menin as a promoter of epithelial-mesenchymal transition (EMT), which is largely associated with cell migration or metastasis, with modest activity in cell growth inhibition. Ectopic expression of Menin suppresses the expression of CCAAT/enhancer-binding protein beta (CEBPB) and epithelial-specific genes by histone deacetylation and further enhances the TGF-β signaling-related EMT process. We also demonstrate that CCAAT/enhancer binding protein (C/EBP) beta (C/EBPβ; encoded by CEBPB) acts downstream of Menin and TGF-β signaling for balancing growth inhibition and EMT, and C/EBPβ overexpression could restore the anti-cancer functions of Menin in pancreatic cancer by cooperatively activating CDKN2A/B genes and antagonizing EMT processes. Taken together, our results suggest that Menin functions as an oncogene for cancer metastasis upon C/EBPβ depletion or acts as a tumor suppressor by cooperation with C/EBPβ to activate CDKN2A transcription.

3 December 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
XXXiongfei Xu
Xiongfei Xu
XCXiuxiao Chen
Xiuxiao Chen
HGHaihui Gu
Haihui Gu
ZCZhanshan Cha
Zhanshan Cha
XSXiaohan Shi
Xiaohan Shi
GJGang Jin
Gang Jin
T cells targeting a KRAS mutation can induce durable tumor regression in some patients with metastatic epithelial cancer. It is unknown whether T cells targeting mutant KRAS that are capable of killing tumor cells can be identified from peripheral blood of patients with pancreatic cancer. We developed an in vitro stimulation approach and identified HLA-A*11:01–restricted KRAS G12V–reactive CD8 + T cells and HLA-DRB1*15:01–restricted KRAS G12V–reactive CD4 + T cells from peripheral blood of 2 out of 6 HLA-A*11:01–positive patients with pancreatic cancer whose tumors expressed KRAS G12V. The HLA-A*11:01–restricted KRAS G12V–reactive T cell receptor (TCR) was isolated and validated to specifically recognize the KRAS G12V 8–16 neoepitope. While T cells engineered to express this TCR specifically recognized all 5 tested human HLA-A*11:01 + and KRAS G12V + pancreatic cancer organoids, the recognition was often modest, and tumor cell killing was observed in only 2 out of 5 organoids. IFN-γ priming of the organoids enhanced the recognition and killing by the TCR-engineered T cells. The TCR-engineered T cells could significantly slow the growth of an established organoid-derived xenograft in immunodeficient mice. Our data suggest that this TCR has potential for use in TCR-gene therapy, but additional strategies that enhance tumor recognition by the TCR-engineered T cells likely will be required to increase clinical activity.

5 August 2025 in iScience
Verified
Journal Article
Open access
CNChenming Ni
Chenming Ni
JYJiacheng Yang
Jiacheng Yang
YLYebin Lu
Yebin Lu
HMHongyun Ma
Hongyun Ma
HHHao Hu
Hao Hu
PCPeng Cheng
Peng Cheng
Pancreatic ductal adenocarcinoma (PDAC) has a bleak prognosis, often driven by aberrant metabolic reprogramming, particularly glycolysis. This study investigated Menin's role in PDAC metabolism. We found that Menin overexpression significantly suppressed glycolytic markers and activity in PDAC cell lines, a suppression that was reversed by HKDC1 knockdown. Mechanistically, Menin interacts with YBX1, facilitating its nuclear translocation to enhance HKDC1 transcription. In vivo, Menin overexpression inhibited tumor growth and glycolysis in xenograft models. These findings indicate that Menin is a critical regulator of PDAC metabolism through the Menin-YBX1-HKDC1 axis, suggesting its potential as a therapeutic target for pancreatic cancer.